Real-time Estimate
Cboe BZX
09:35:00 2024-06-14 am EDT
|
5-day change
|
1st Jan Change
|
4.44
USD
|
-1.33%
|
|
-4.46%
|
+83.78%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
439.8
|
460.2
|
84.01
|
53.44
|
19.64
|
12.69
|
Enterprise Value (EV)
1 |
437.1
|
460.4
|
54.82
|
45.29
|
24.51
|
10.91
|
P/E ratio
|
-28.6
x
|
-24.6
x
|
12.4
x
|
-2.1
x
|
-2
x
|
-3.92
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,147
x
|
860
x
|
92.2
x
|
34.7
x
|
15.2
x
|
29.4
x
|
EV / Revenue
|
1,140
x
|
860
x
|
60.1
x
|
29.4
x
|
18.9
x
|
25.3
x
|
EV / EBITDA
|
-45.2
x
|
-27.2
x
|
-2.97
x
|
-2.51
x
|
-1.5
x
|
-1.14
x
|
EV / FCF
|
-16.1
x
|
162
x
|
-6.06
x
|
-4.09
x
|
-3.48
x
|
-2.74
x
|
FCF Yield
|
-6.19%
|
0.62%
|
-16.5%
|
-24.4%
|
-28.7%
|
-36.5%
|
Price to Book
|
13.3
x
|
28.1
x
|
2.01
x
|
2.26
x
|
1.25
x
|
0.51
x
|
Nbr of stocks (in thousands)
|
2,898
|
2,904
|
3,401
|
3,563
|
3,571
|
5,182
|
Reference price
2 |
151.8
|
158.5
|
24.70
|
15.00
|
5.501
|
2.449
|
Announcement Date
|
4/15/19
|
4/29/20
|
4/19/21
|
4/29/22
|
4/28/23
|
4/30/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.3834
|
0.5352
|
0.9115
|
1.542
|
1.296
|
0.4314
|
EBITDA
1 |
-9.665
|
-16.9
|
-18.43
|
-18.02
|
-16.3
|
-9.599
|
EBIT
1 |
-10.33
|
-18.2
|
-19.69
|
-19.21
|
-17.51
|
-10.72
|
Operating Margin
|
-2,693.47%
|
-3,400.52%
|
-2,160.69%
|
-1,245.77%
|
-1,351.13%
|
-2,486.04%
|
Earnings before Tax (EBT)
1 |
-15.13
|
-20.12
|
4.92
|
-27.11
|
-11.53
|
-4.341
|
Net income
1 |
-14.83
|
-18.69
|
7.067
|
-25.05
|
-9.8
|
-2.825
|
Net margin
|
-3,867.97%
|
-3,491.77%
|
775.29%
|
-1,624.64%
|
-756.2%
|
-654.8%
|
EPS
2 |
-5.314
|
-6.442
|
2.000
|
-7.150
|
-2.750
|
-0.6248
|
Free Cash Flow
1 |
-27.08
|
2.835
|
-9.047
|
-11.07
|
-7.042
|
-3.985
|
FCF margin
|
-7,061.55%
|
529.67%
|
-992.53%
|
-718.15%
|
-543.44%
|
-923.76%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/15/19
|
4/29/20
|
4/19/21
|
4/29/22
|
4/28/23
|
4/30/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
0.22
|
-
|
-
|
4.87
|
-
|
Net Cash position
1 |
2.73
|
-
|
29.2
|
8.15
|
-
|
1.78
|
Leverage (Debt/EBITDA)
|
-
|
-0.0132
x
|
-
|
-
|
-0.2987
x
|
-
|
Free Cash Flow
1 |
-27.1
|
2.83
|
-9.05
|
-11.1
|
-7.04
|
-3.98
|
ROE (net income / shareholders' equity)
|
-48.1%
|
-84.5%
|
18.6%
|
-97.4%
|
-91%
|
-37.4%
|
ROA (Net income/ Total Assets)
|
-16.8%
|
-33%
|
-36.1%
|
-36.3%
|
-51.2%
|
-32.3%
|
Assets
1 |
88.04
|
56.7
|
-19.57
|
69
|
19.15
|
8.746
|
Book Value Per Share
2 |
11.40
|
5.630
|
12.30
|
6.620
|
4.400
|
4.790
|
Cash Flow per Share
2 |
4.140
|
1.790
|
1.030
|
2.280
|
0.5300
|
0.3900
|
Capex
1 |
5.65
|
0.84
|
0.16
|
0.13
|
0.19
|
0
|
Capex / Sales
|
1,472.55%
|
156.41%
|
17.7%
|
8.55%
|
14.42%
|
0.7%
|
Announcement Date
|
4/15/19
|
4/29/20
|
4/19/21
|
4/29/22
|
4/28/23
|
4/30/24
|
|
1st Jan change
|
Capi.
|
---|
| +83.78% | 24.62M | | +51.54% | 795B | | +42.03% | 627B | | -7.20% | 350B | | +18.67% | 328B | | +7.48% | 294B | | +17.92% | 245B | | +1.43% | 222B | | +12.17% | 215B | | +3.64% | 160B |
Other Pharmaceuticals
|